Amply™Technology has demonstrated productivity increase from milligrams/L to grams/L, for monoclonal antibodies or difficult to express proteins for therapeutic application.
CHO : Chinese Hamster Ovary (CHO) is currently the most frequently used cellular platform for therapeutic protein production(Walsh 2014).
Origin : CHO cells were firstly isolated in 1957 in Theodore puck’s laboratory from ovary tissue. At first, CHO cells exhibit a fibroblastic morphology in combination with adherent culture. After 10 months, part of the CHO cells population evolved toward an epithelial morphology. These cells were distributed to laboratories worldwide and some CHO cells have adapted to suspension culture(Wurm 2013).
Main characteristics : the CHO platform presents numerous advantageous features for recombinant protein production. CHO cells are not much affected by virus infection, glycosylation profile similar to the human profile, easy and fast growth and high-yield productivity.
Applications : most biopharmaceuticals currently commercialized are generated in CHO cells.
Our experience : AmplyCell successfully increased CHO cells specific productivity. These great results were obtained with different CHO cell lines such as CHO-DG44 and CHO-K1. We can also work on the parental non-producing cell line.
Amply™ Technology may also be applied on producing cells or on your parental non-transfected cells.
Walsh, Gary. 2014. “Biopharmaceutical Benchmarks 2014.” Nature biotechnology 32(7): 992–1000.
Wurm, Florian. 2013. “CHO Quasispecies—Implications for Manufacturing Processes.” Processes 1(3): 296–311. http://www.mdpi.com/2227-9717/1/3/296/.
Your super-CHO cells (in orange) keep on maintaining high production level in a stable way, along passages!